Search Results - "CRUICKSHANK, Scott"

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor by YARDLEY, Denise A, ISMAIL-KHAN, Roohi R, MELICHAR, Bohuslav, LICHINITSER, Mikhail, MUNSTER, Pamela N, KLEIN, Pamela M, CRUICKSHANK, Scott, MILLER, Kathy D, LEE, Min J, TREPEL, Jane B

“…Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast…”
Get full text

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial by Hambardzumyan, Karen, Bolce, Rebecca, Saevarsdottir, Saedis, Cruickshank, Scott E, Sasso, Eric H, Chernoff, David, Forslind, Kristina, Petersson, Ingemar F, Geborek, Pierre, van Vollenhoven, Ronald F

“…Prediction of radiographic progression (RP) in early rheumatoid arthritis (eRA) would be very useful for optimal choice among available therapies. We evaluated…”
Get more information

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer by Yardley, Denise A, Weaver, Robert, Melisko, Michelle E, Saleh, Mansoor N, Arena, Francis P, Forero, Andres, Cigler, Tessa, Stopeck, Alison, Citrin, Dennis, Oliff, Ira, Bechhold, Rebecca, Loutfi, Randa, Garcia, Agustin A, Cruickshank, Scott, Crowley, Elizabeth, Green, Jennifer, Hawthorne, Thomas, Yellin, Michael J, Davis, Thomas A, Vahdat, Linda T

“…Glycoprotein NMB (gpNMB), a negative prognostic marker, is overexpressed in multiple tumor types. Glembatumumab vedotin is a gpNMB-specific monoclonal antibody…”
Get full text

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma by Batlevi, Connie Lee, Kasamon, Yvette, Bociek, R Gregory, Lee, Peter, Gore, Lia, Copeland, Amanda, Sorensen, Rachel, Ordentlich, Peter, Cruickshank, Scott, Kunkel, Lori, Buglio, Daniela, Hernandez-Ilizaliturri, Francisco, Younes, Anas

“…Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint…”
Get full text

A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease by Hockenbery, David M., Cruickshank, Scott, Rodell, Timothy C., Gooley, Ted, Schuening, Friedrich, Rowley, Scott, David, Donald, Brunvand, Mark, Berryman, Brian, Abhyankar, Sunil, Bouvier, Michelle, McDonald, George B.

“…We tested the hypothesis that oral beclomethasone dipropionate (BDP) would control gastrointestinal graft-versus-host disease (GVHD) in patients with anorexia,…”
Get full text

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial by Hambardzumyan, Karen, Bolce, Rebecca J, Saevarsdottir, Saedis, Forslind, Kristina, Wallman, Johan K, Cruickshank, Scott E, Sasso, Eric H, Chernoff, David, van Vollenhoven, Ronald F

“…ObjectivesIn rheumatoid arthritis (RA), predictive biomarkers for subsequent radiographic progression (RP) could improve therapeutic choices for individual…”
Get full text

Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon-α2b, and Recombinant Interleukin-2 for the Treatment of Metastatic Melanoma by WEBER, Robert W, O'DAY, Steven, CRUICKSHANK, Scott, COOK, Mary, GONZALEZ, Rene, SPITLER, Lynn E, ROSE, Madalene, DECK, Regina, AMES, Patricia, GOOD, James, MEYER, John, ALLEN, Robert, TRAUTVETTER, Sharon, TIMMERMAN, Molly

Get full text

Increasing Chemotherapy Dose Density and Intensity: Phase I Trials in Non‐Small Cell Lung Cancer and Non‐Hodgkin's Lymphoma by Blayney, Douglas W., McGuire, Brian W., Cruickshank, Scott E., Johnson, David H.

“…Dose densification and dose escalation of cytotoxic chemotherapy may be important in improving the cure rates of chemotherapy‐responsive cancers. We conducted…”
Get full text

Abstract CT136: STELLAR: A phase 3, randomized, open-label study to evaluate the efficacy and safety of eflornithine with lomustine compared to lomustine alone in patients with anaplastic astrocytoma that progress/recur after irradiation and adjuvant temozolomide chemotherapy by Levin, Victor A., Cruickshank, Scott

“…Abstract Background: Eflornithine, a novel cytostatic agent, irreversibly inhibits ornithine decarboxylase, the enzyme that catalyzes the first step in the…”
Get full text

STELLAR: A phase 3, randomized, open-label study of eflornithine with lomustine vs lomustine for patients with first recurrence of anaplastic astrocytoma after RT and adjuvant temozolomide by Levin, Victor A., Cruickshank, Scott

“…Abstract only TPS2081 Background: Eflornithine irreversibly inhibits ornithine decarboxylase an enzyme that catalyzes the biosynthesis of putrescine, one of 3…”
Get full text

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study by Laetsch, Theodore W, DuBois, Steven G, Mascarenhas, Leo, Turpin, Brian, Federman, Noah, Albert, Catherine M, Nagasubramanian, Ramamoorthy, Davis, Jessica L, Rudzinski, Erin, Feraco, Angela M, Tuch, Brian B, Ebata, Kevin T, Reynolds, Mark, Smith, Steven, Cruickshank, Scott, Cox, Michael C, Pappo, Alberto S, Hawkins, Douglas S

“…Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a broad range of paediatric and adult malignancies. Larotrectinib, a highly selective…”
Get full text

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial by Reardon, David A, Desjardins, Annick, Vredenburgh, James J, O'Rourke, Donald M, Tran, David D, Fink, Karen L, Nabors, Louis B, Li, Gordon, Bota, Daniela A, Lukas, Rimas V, Ashby, Lynn S, Duic, J Paul, Mrugala, Maciej M, Cruickshank, Scott, Vitale, Laura, He, Yi, Green, Jennifer A, Yellin, Michael J, Turner, Christopher D, Keler, Tibor, Davis, Thomas A, Sampson, John H

“…Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to…”
Get full text

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas by DuBois, Steven G., Laetsch, Theodore W., Federman, Noah, Turpin, Brian K., Albert, Catherine M., Nagasubramanian, Ramamoorthy, Anderson, Megan E., Davis, Jessica L., Qamoos, Hope E., Reynolds, Mark E., Cruickshank, Scott, Cox, Michael C., Hawkins, Douglas S., Mascarenhas, Leo, Pappo, Alberto S.

“…Background The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK…”
Get full text

‘Chemobrain’ in breast carcinoma? by Wefel, Jeffrey S., Lenzi, Renato, Theriault, Richard, Buzdar, Aman U., Cruickshank, Scott, Meyers, Christina A.

“…BACKGROUND Chemotherapy‐induced cognitive dysfunction in patients with breast carcinoma has been described previously. However, those studies only assessed…”
Get full text

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study by Schuster, James, Lai, Rose K, Recht, Lawrence D, Reardon, David A, Paleologos, Nina A, Groves, Morris D, Mrugala, Maciej M, Jensen, Randy, Baehring, Joachim M, Sloan, Andrew, Archer, Gary E, Bigner, Darell D, Cruickshank, Scott, Green, Jennifer A, Keler, Tibor, Davis, Thomas A, Heimberger, Amy B, Sampson, John H

“…The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary glioblastoma and linked to poor long-term…”
Get full text

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat by Tomita, Yusuke, Lee, Min-Jung, Lee, Sunmin, Tomita, Saori, Chumsri, Saranya, Cruickshank, Scott, Ordentlich, Peter, Trepel, Jane B

“…Entinostat, a class I-selective histone deacetylase inhibitor, has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial of…”
Get full text

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Adult Subjects with NTRK Fusion-Positive Tumors by Drilon, Alexander E., Hong, David S., Cruickshank, Scott, Deegan, Maegan, Ku, Nora, Hyman, David Michael

“…Abstract only…”
Get full text

Abstract PR07: A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: An updated analysis by Turpin, Brian, Albert, Catherine M., Mascarenhas, Leo, Federman, Noah, Nagasubramanian, Ramamoorthy, Reynolds, Mark, Smith, Steven, Cruickshank, Scott, Cox, Michael C., Pappo, Alberto S., Hawkins, Douglas S., DuBois, Steven G., Laetsch, Theodore W.

“…Abstract Background: NTRK gene fusions occur in a broad range of pediatric and adult malignancies at low frequencies, but are present in the vast majority of…”
Get full text

Biologic Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated with GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma by Spitler, Lynn E., Cao, Huynh, Piironen, Timo, Whiteside, Theresa L., Weber, Robert W., Cruickshank, Scott

Get full text

Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma by Spitler, Lynn E, Boasberg, Peter, O'Day, Steven, Hamid, Omid, Cruickshank, Scott, Mesko, Shane, Weber, Robert W

“…This study was an open-label multicenter phase II trial to investigate the efficacy and safety of nab-paclitaxel and bevacizumab as first-line therapy in…”
Get full text